Malaria - Pipeline Review, H1 2017

  • ID: 4267369
  • Report
  • 365 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4SC AG
  • AstraZeneca Plc
  • GenVec Inc
  • Imaxio SA
  • Lipocure Ltd
  • Novartis AG
  • MORE
Malaria - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Malaria - Pipeline Review, H1 2017, provides an overview of the Malaria (Infectious Disease) pipeline landscape.

Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. Treatment includes anti-malarial medicines and healthy lifestyle.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Malaria - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Malaria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malaria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Malaria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 12, 10, 55 and 31 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 11, 45 and 41 molecules, respectively.

Malaria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Malaria (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Malaria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Malaria (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Malaria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Malaria (Infectious Disease)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Malaria (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Malaria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4SC AG
  • AstraZeneca Plc
  • GenVec Inc
  • Imaxio SA
  • Lipocure Ltd
  • Novartis AG
  • MORE
Introduction

Malaria - Overview

Malaria - Therapeutics Development

Malaria - Therapeutics Assessment

Malaria - Companies Involved in Therapeutics Development

Malaria - Drug Profiles

Malaria - Dormant Projects

Malaria - Discontinued Products

Malaria - Product Development Milestones

Appendix

List of Tables:

Number of Products under Development for Malaria, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Companies, H1 2017 (Contd..2), H1

Number of Products under Development by Companies, H1 2017 (Contd..3), H1

Number of Products under Development by Universities/Institutes, H1

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Companies, H1 2017 (Contd..2), H1

Products under Development by Companies, H1 2017 (Contd..3), H1

Products under Development by Companies, H1 2017 (Contd..4), H1

Products under Development by Companies, H1 2017 (Contd..5), H1

Products under Development by Universities/Institutes, H1

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1

Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1

Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1

Products under Development by Universities/Institutes, H1 2017 (Contd..5), H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Target, H1 2017 (Contd..1), H1

Number of Products by Stage and Target, H1 2017 (Contd..2), H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Malaria - Pipeline by 4SC AG, H1

Malaria - Pipeline by Actelion Ltd, H1

Malaria - Pipeline by Agilvax Inc, H1

Malaria - Pipeline by Akshaya Bio Inc, H1

Malaria - Pipeline by Alfa Wassermann SpA, H1

Malaria - Pipeline by Allergy Therapeutics Plc, H1

Malaria - Pipeline by Altimmune Inc, H1

Malaria - Pipeline by Amura Holdings Ltd, H1

Malaria - Pipeline by Anacor Pharmaceuticals Inc, H1

Malaria - Pipeline by Artificial Cell Technologies Inc, H1

Malaria - Pipeline by AstraZeneca Plc, H1

Malaria - Pipeline by Atreca Inc, H1

Malaria - Pipeline by Bharat Biotech International Ltd, H1

Malaria - Pipeline by Carna Biosciences Inc, H1

Malaria - Pipeline by CEL-SCI Corp, H1

Malaria - Pipeline by Celgene Corp, H1

Malaria - Pipeline by Cilian AG, H1

Malaria - Pipeline by Daiichi Sankyo Company Ltd, H1

Malaria - Pipeline by DesignMedix Inc, H1

Malaria - Pipeline by Eisai Co Ltd, H1

Malaria - Pipeline by GenVec Inc, H1

Malaria - Pipeline by Genzyme Corp, H1

Malaria - Pipeline by GeoVax Labs Inc, H1

Malaria - Pipeline by GlaxoSmithKline Plc, H1

Malaria - Pipeline by Griffith University, H1

Malaria - Pipeline by Hager Biosciences LLC, H1

Malaria - Pipeline by iBio Inc, H1

Malaria - Pipeline by Ichor Medical Systems Inc, H1

Malaria - Pipeline by Imaxio SA, H1

Malaria - Pipeline by Immtech Pharmaceuticals Inc, H1

Malaria - Pipeline by Immunovaccine Inc, H1

Malaria - Pipeline by IPCA Laboratories Ltd, H1

Malaria - Pipeline by IRBM Science Park SpA, H1

Malaria - Pipeline by Jenrin Discovery Inc, H1

Malaria - Pipeline by Jomaa Pharma GmbH, H1

Malaria - Pipeline by Kancera AB, H1

Malaria - Pipeline by Kymab Ltd, H1

Malaria - Pipeline by Lipocure Ltd, H1

Malaria - Pipeline by Lipotek Pty Ltd, H1

Malaria - Pipeline by LondonPharma Ltd, H1

Malaria - Pipeline by Marinomed Biotechnologie GmbH, H1

Malaria - Pipeline by Merck & Co Inc, H1

Malaria - Pipeline by Merck KGaA, H1

Malaria - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1

Malaria - Pipeline by Microbiotix Inc, H1

Malaria - Pipeline by Mitsubishi Tanabe Pharma Corp, H1

Malaria - Pipeline by Mucosis BV, H1

Malaria - Pipeline by Mymetics Corp, H1

Malaria - Pipeline by Novartis AG, H1

Malaria - Pipeline by PaxVax Inc, H1

Malaria - Pipeline by Pfizer Inc, H1

Malaria - Pipeline by Protein Potential LLC, H1

Malaria - Pipeline by Rodos BioTarget GmbH, H1

Malaria - Pipeline by Sanaria Inc, H1

Malaria - Pipeline by Sanofi, H1

Malaria - Pipeline by SBI Pharmaceuticals Co Ltd, H1

Malaria - Pipeline by Selecta Biosciences Inc, H1

Malaria - Pipeline by Takeda Pharmaceutical Company Ltd, H1

Malaria - Pipeline by Theravectys SA, H1

Malaria - Pipeline by Tomegavax Inc, H1

Malaria - Pipeline by Toyama Chemical Co Ltd, H1

Malaria - Pipeline by VLP Biotech Inc, H1

Malaria - Pipeline by VLP Therapeutics LLC, H1

Malaria - Pipeline by Zydus Cadila Healthcare Ltd, H1

Malaria - Dormant Projects, H1

Malaria - Dormant Projects, H1 2017 (Contd..1), H1

Malaria - Dormant Projects, H1 2017 (Contd..2), H1

Malaria - Dormant Projects, H1 2017 (Contd..3), H1

Malaria - Dormant Projects, H1 2017 (Contd..4), H1

Malaria - Dormant Projects, H1 2017 (Contd..5), H1

Malaria - Dormant Projects, H1 2017 (Contd..6), H1

Malaria - Dormant Projects, H1 2017 (Contd..7), H1

Malaria - Discontinued Products, H1

Malaria - Discontinued Products, H1 2017 (Contd..1), H1

List of Figures:

Number of Products under Development for Malaria, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Top 10 Molecule Types, H1

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 4SC AG
  • Actelion Ltd
  • Agilvax Inc
  • Akshaya Bio Inc
  • Alfa Wassermann SpA
  • Allergy Therapeutics Plc
  • Altimmune Inc
  • Amura Holdings Ltd
  • Anacor Pharmaceuticals Inc
  • Artificial Cell Technologies Inc
  • AstraZeneca Plc
  • Atreca Inc
  • Bharat Biotech International Ltd
  • Carna Biosciences Inc
  • CEL-SCI Corp
  • Celgene Corp
  • Cilian AG
  • Daiichi Sankyo Company Ltd
  • DesignMedix Inc
  • Eisai Co Ltd
  • GenVec Inc
  • Genzyme Corp
  • GeoVax Labs Inc
  • GlaxoSmithKline Plc
  • Griffith University
  • Hager Biosciences LLC
  • iBio Inc
  • Ichor Medical Systems Inc
  • Imaxio SA
  • Immtech Pharmaceuticals Inc
  • Immunovaccine Inc
  • IPCA Laboratories Ltd
  • IRBM Science Park SpA
  • Jenrin Discovery Inc
  • Jomaa Pharma GmbH
  • Kancera AB
  • Kymab Ltd
  • Lipocure Ltd
  • Lipotek Pty Ltd
  • LondonPharma Ltd
  • Marinomed Biotechnologie GmbH
  • Merck & Co Inc
  • Merck KGaA
  • MerLion Pharmaceuticals Pte Ltd
  • Microbiotix Inc
  • Mitsubishi Tanabe Pharma Corp
  • Mucosis BV
  • Mymetics Corp
  • Novartis AG
  • PaxVax Inc
  • Pfizer Inc
  • Protein Potential LLC
  • Rodos BioTarget GmbH
  • Sanaria Inc
  • Sanofi
  • SBI Pharmaceuticals Co Ltd
  • Selecta Biosciences Inc
  • Takeda Pharmaceutical Company Ltd
  • Theravectys SA
  • Tomegavax Inc
  • Toyama Chemical Co Ltd
  • VLP Biotech Inc
  • VLP Therapeutics LLC
  • Zydus Cadila Healthcare Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll